EUVIMEDScopri EUVIMED
Crossref

Protection of SARS‐CoV‐2 Infection by Targeting Viral Spike Protein With De Novo Designed ACE2‐Derived Undecapeptide

Anindya Dutta, Nilanjan Banerjee, Soushruti Sarkar, Abhishek Sen, Partha Chakrabarti, Ananya Dutta, Kuladip Jana, Gopeswar Mukherjee, Samit Chattopadhyay, Subhrangsu Chatterjee

Journal of Peptide Science · 2026-07 · 32 (7)

DOI: 10.1002/psc.70097 ↗

At a glance

Journal article in Journal of Peptide Science, published online on 2026-05-27. Written by Anindya Dutta and 9 co-authors. Institution: BITS-BioCyTIH Foundation, Birla Institute of Technology and Science (BITS) Pilani, Mormugao, South Goa, India. Major MEDLINE topics: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Peptidyl-Dipeptidase A, Antiviral Agents. 44 references. Funded by: BITS-BioCyTIH Foundation, Bose Institute.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The envelope‐anchored trimeric spike protein of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) mediates the attachment and entry of the virus within human cells by utilizing the angiotensin converting enzyme 2 (ACE2) as a receptor, present in the epithelial cells of the upper respiratory tract and lungs. The ACE2 interaction interface with the SARS‐CoV‐2 spike protein was utilized to design an ACE2‐derived peptide sequence (FD11) that targeted the viral spike protein. It was found to be non‐cell penetrating, while in vivo studies revealed the non‐cytotoxic nature of the peptide molecule. The minimum effective concentration of the peptide was found to be 10 μM with 95% cell viability in Vero E6 cell line. The IC 50 of the peptide was found to be around 6.4 μM. Treatment of the peptide in SARS‐CoV‐2 infected Vero E6 cells was found to decrease the infectivity as compared to control. This presents a simple approach where host‐pathogen protein interaction‐interface derived peptides can be used for binding with substrate macromolecules to target and modulate pathogen infectivity.

Subjects

MeSH terms (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2Peptidyl-Dipeptidase AAntiviral AgentsPeptidesAnimalsAngiotensin-Converting Enzyme 2Vero CellsHumansChlorocebus aethiopsCOVID-19Virus Internalization

Author keywords

ACE2SARS‐CoV‐2non‐cell penetratingpeptidespike protein

Substances

Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2spike protein, SARS-CoV-2ACE2 protein, humanPeptidyl-Dipeptidase AAntiviral AgentsPeptides

Authors and institutions

  • BITS-BioCyTIH Foundation, Birla Institute of Technology and Science (BITS) Pilani, Mormugao, South Goa, India.
  • Bose Institute, Kolkata, West Bengal, India.
  • CSIR-Indian Institute of Chemical Biology (IICB), Kolkata, West Bengal, India.
  • Barasat Cancer Research and Welfare Centre, Kolkata, West Bengal, India.

Funding

  • BITS-BioCyTIH Foundation
  • Bose Institute

Cite

APA

Dutta, A., Banerjee, N., Sarkar, S., Sen, A., Chakrabarti, P., Dutta, A., Jana, K., Mukherjee, G., Chattopadhyay, S., & Chatterjee, S. (2026). Protection of SARS‐CoV‐2 Infection by Targeting Viral Spike Protein With De Novo Designed ACE2‐Derived Undecapeptide. Journal of Peptide Science, 32(7). https://doi.org/10.1002/psc.70097

Vancouver

Dutta A, Banerjee N, Sarkar S, Sen A, Chakrabarti P, Dutta A, et al. Protection of SARS‐CoV‐2 Infection by Targeting Viral Spike Protein With De Novo Designed ACE2‐Derived Undecapeptide. Journal of Peptide Science. 2026;32(7). doi:10.1002/psc.70097

BibTeX
@article{Dutta2026,
  author = {Dutta, Anindya and Banerjee, Nilanjan and Sarkar, Soushruti and Sen, Abhishek and Chakrabarti, Partha and Dutta, Ananya and Jana, Kuladip and Mukherjee, Gopeswar and Chattopadhyay, Samit and Chatterjee, Subhrangsu},
  title = {Protection of SARS‐CoV‐2 Infection by Targeting Viral Spike Protein With De Novo Designed ACE2‐Derived Undecapeptide},
  journal = {Journal of Peptide Science},
  year = {2026},
  volume = {32},
  number = {7},
  doi = {10.1002/psc.70097}
}
Start for free →